CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 228 enrolled
Drug / intervention
ESK-001 +1 moredrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓Age 18–75 years
  • ✓Body weight >40 kg (88 lb)
Key exclusion· 6
  • ✕History of malignancy within the last 5 years
  • ✕Positive for HIV, Hepatitis B, or Hepatitis C
  • ✕History of tuberculosis
  • ✕Non-plaque psoriasis diagnosis

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05600036
NCT05600036Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

Alumis Inc·interventional·Posted Oct 31, 2022·Updated Jun 18, 2025

In Brief

A Phase 2 clinical trial evaluating ESK-001 and Placebo for Plaque Psoriasis. Completed, enrolled 228 participants across 53 sites in 3 countries.

Detailed Summary

This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, Czechia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedOct 31, 2022
Enrollment StartSep 27, 2022
Primary CompletionJun 29, 2023
Study CompletionJul 25, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.7 years ago

Interventions

ESK-001drug

Oral tablet

Placebodrug

Oral tablet